Reports
Sale
Global Cancer Microbiome Market Size, Share, Trends, Analysis, Report: By Type: Products, Services; By End User: Hospitals, Diagnostic Labs; Market Dynamics; Regional Analysis; Patent Analysis; Grants Analysis; Clinical Trials Analysis; Funding and Investment Analysis; Partnership and Collaborations Analysis; Supplier Landscape; 2024-2032
Global Cancer Microbiome Market Outlook
The global cancer microbiome market size was valued at USD 267.14 million in 2023, driven by the increasing prevalence of chronic cancers across the globe. The market size is anticipated to grow at a CAGR of 19.9% during the forecast period of 2024-2032 to achieve a value of USD 1,368.07 million by 2032.
Cancer Microbiome: Introduction
Microbiome refers to the population of microorganisms, including bacteria, viruses, and fungi, that exist in the human body. Cancer microbiomes, also known as tumor microbiomes, are a group of microorganisms that live in and around cancerous tumors in the human body. These microorganisms can either promote or inhibit tumor growth, depending on their effects on cancer.
The cancer microbiome offers several advantages, including the potential to gain insights into the development and spread of cancer. This understanding could help in devising strategies to prevent cancer progression or metastasis. By identifying specific microbes that either stimulate or hinder tumor growth, targeted therapies could also be developed.
Global Cancer Microbiome Market Analysis
The increasing number of clinical studies to explore the potential of microbiomes in managing responses against cancer treatments are acting as a major trend for the global cancer microbiome market growth in the coming years. For example, a study was published in the Journal of Clinical Oncology studying the microbiomes with advanced biliary tract cancer to observe their response against a new treatment that combines durvalumab with cisplatin and gemcitabine.
The growing demand for personalized medicine worldwide is driving the global market for cancer microbiome further. The increasing number of research and development activities and increasing collaborations between the microbiome industry and academia to utilize the resources and expertise of both are likely to add significant growth to the overall global cancer microbiome market share.
In addition, increasing collaboration between key players and innovative companies to develop transformative advancements is also expected to drive the market growth. For example, The University of Texas MD Anderson Cancer Centre and Federation Bio have partnered to create a synthetic microbial consortium, which aims to expand the number of cancer patients responding to immunotherapy.
Key biotech companies are also raising funds from investors interested in the development of new cancer treatments with the help of microbiome potential. For instance, Enterome, a biotech company, aims to raise USD 108 million for its clinical studies and support clinical trials, including two Phase II studies.
Pragma Bio has also raised a whopping USD 10 million in funding. The startup aims to initiate the first part of a 10-year plan. Pragma is using artificial intelligence to create a statistical model that identifies potential candidates for microbiome investigation. The first area of focus for augmentation is immunotherapy in oncology, which has a close relationship with the microbiome. The first area of focus for augmentation is immunotherapy in oncology, which has a close relationship with microbiome.
Global Cancer Microbiome Market Segmentations
Market Breakup by Type
- Products
- Services
Market Breakup by End User
- Hospitals
- Diagnostic Labs
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Cancer Microbiome Market Overview
The increasing prevalence of chronic cancers across the globe is a major factor driving the growth of the market. The increasing demand for personalized cancer treatments is also influencing the market growth. The increasing use of genome sequencing in exploring the potential of microbiome in cancer treatments, as it helps researchers to analyze the composition of microbial communities in and around cancerous tissues, is also expected to drive the market growth. The continuous advancements in research and development activities also act as a major factor driving the global cancer microbiome market growth.
The market development is also driven by the heavy investments by pharmaceutical companies, government agencies, and private investors, in microbiome research for cancer and the development of new therapies and products. The increased number of clinical trials to explore and create microbiome-based treatments for cancer is gaining popularity in the market, further propelling the market growth.
Global Cancer Microbiome Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Novogene Corporation
- Psomagen
- PerkinElmer Genomics
- Illumina
- Thermo Fisher Scientific
- Viome
- Invivo Healthcare
- Zymo Research Corp
- Metabiomics
- CD Genomics
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Cancer Microbiome Overview
3.1 Guidelines and stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Cancer Microbiome Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Cancer Microbiome Epidemiology (2016-2031)
5.3 Europe Cancer Microbiome Epidemiology (2016-2031)
5.4 Asia-Pacific Cancer Microbiome Epidemiology (2016-2031)
5.5 Latin America Cancer Microbiome Epidemiology (2016-2031)
5.6 Middle East & Africa Cancer Microbiome Epidemiology (2016-2031)
6 Global Cancer Microbiome Market Overview
6.1 Global Cancer Microbiome Market Historical Value (2017-2023)
6.2 Global Cancer Microbiome Market Forecast Value (2024-2032)
7 Global Cancer Microbiome Market Landscape
7.1 Cancer Microbiome: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Cancer Microbiome: Product Landscape
7.2.1 Analysis by Type
7.2.2 Analysis by End User
8 Global Cancer Microbiome Market Dynamics
8.1 Market Drivers and Constraints
8.2 SWOT Analysis
8.3 Porter’s Five Forces Model
8.4 Key Demand Indicators
8.5 Key Price Indicators
8.6 Industry Events, Initiatives, and Trends
8.7 Value Chain Analysis
9 Global Cancer Microbiome Market Segmentation
9.1 Global Cancer Microbiome Market by Type
9.1.1 Market Overview
9.1.2 Products
9.1.3 Services
9.2 Global Cancer Microbiome Market by End User
9.2.1 Market Overview
9.2.2 Hospitals
9.2.3 Diagnostic Labs
9.3 Global Cancer Microbiome Market by Region
9.3.1 Market Overview
9.3.2 North America
9.3.3 Europe
9.3.4 Asia Pacific
9.3.5 Latin America
9.3.6 Middle East and Africa
10 North America Cancer Microbiome Market
10.1 Market Share by Country
10.2 United States of America
10.3 Canada
11 Europe Cancer Microbiome Market
11.1 Market Share by Country
11.2 United Kingdom
11.3 Germany
11.4 France
11.5 Italy
11.6 Others
12 Asia Pacific Cancer Microbiome Market
12.1 Market Share by Country
12.2 China
12.3 Japan
12.4 India
12.5 ASEAN
12.6 Australia
12.7 Others
13 Latin America Cancer Microbiome Market
13.1 Market Share by Country
13.2 Brazil
13.3 Argentina
13.4 Mexico
13.5 Others
14 Middle East and Africa Cancer Microbiome Market
14.1 Market Share by Country
14.2 Saudi Arabia
14.3 United Arab Emirates
14.4 Nigeria
14.5 South Africa
14.6 Others
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 INDIA CDSCO
15.1.4 JAPAN PMDA
15.1.5 Others
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnership and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 Novogene Corporation
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 Psomagen
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 PerkinElmer Genomics
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 Illlumina
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 Thermo Fisher Scientific
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 Viome
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 Invivo Healthcare
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 Zymo Research Corp
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 Metabiomics
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 CD Genomics
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
22 Key Opinion Leaders (KOL) Insights (Additional Insight)
23 Company Competitiveness Analysis (Additional Insight)
23.1 Very Small Companies
23.2 Small Companies
23.3 Mid-Sized Companies
23.4 Large Companies
23.5 Very Large Companies
24 Payment Methods (Additional Insight)
24.1 Government Funded
24.2 Private Insurance
24.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 267.14 million in 2023, driven by the increasing research and development.
The market is anticipated to grow at a CAGR of 19.9% during the forecast period of 2024-2032, likely to reach a market value of USD 1,368.07 million by 2032.
The increasing prevalence of chronic diseases, such as cancer, and the increasing demand for personalized medicine are among the major factors driving the market growth for the forecast period.
The key factor influencing the market growth include the increasing collaborations between the microbiome sector, academic institutions, and key players.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America is currently leading the global market.
Key end users in the market include hospitals and diagnostic labs.
Key players involved in the market are Novogene Corporation, Psomagen, PerkinElmer Genomics, Illumina, Thermo Fisher Scientific, Viome, Invivo Healthcare, Zymo Research Corp, Metabiomics, and CD Genomics.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER